Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant.
OBJECTIVE
To report a case of cytomegalovirus (CMV) retinitis after placement of a fluocinolone acetonide (Retisert) implant.


METHODS
Interventional case report.


METHODS
Retrospective chart review.


RESULTS
A 65-year-old man with a history of Adamantiades-Behcet disease and bilateral recurrent uveitis that was unresponsive to systemic corticosteroid-sparing immunosuppressive therapy developed clinical evidence of CMV retinitis after receiving his second intravitreal Retisert implant in the left eye, while on no systemic immunosuppression. He did not develop CMV retinitis in the right eye despite multiple intraocular and periocular steroid injections. The patient responded well to intravitreal foscarnet followed by placement of an intravitreal ganciclovir implant.


CONCLUSIONS
Ophthalmologists should be aware of the potential risk for development of CMV retinitis after local ocular immunosuppressive therapy.
Ufret-Vincenty
Rafael L
RL
Cleveland Clinic Cole Eye Institute, Cleveland, Ohio 44195, USA.
Singh
Rishi P
RP
Lowder
Careen Y
CY
Kaiser
Peter K
PK
D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000150:complications; D017726:Cytomegalovirus Retinitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D004343:Drug Implants; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects*; D017245:Foscarnet / Q000627:therapeutic use; D015774:Ganciclovir / Q000627:therapeutic use; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D012189:Retrospective Studies; D014605:Uveitis / Q000150:complications
D000998:Antiviral Agents; D004343:Drug Implants; D005938:Glucocorticoids; D005446:Fluocinolone Acetonide; D017245:Foscarnet; D015774:Ganciclovir